Resistance to anti-EGFR has been widely documented in patients with HER2 + CRC [11–13]; on the contrary, the prognostic role of HER2+ has not been well established in CRC; nevertheless, the tendency to worse outcomes in survival has been reported in patients with HER2 + CRC [14]. This evidence concerns the gene EGFR and colorectal carcinoma.